EMBO molecular medicine
Cure8 research brief
Why This Matters
Identifies a new molecular checkpoint (RADX versus IFI16) linking replication stress/genome instability to innate immune activation and intestinal inflammation, suggesting potential targets for future IBD treatments or biomarkers.
Who Should Pay Attention
Researchers studying IBD mechanisms, genome instability, or innate immunity; translational scientists and clinicians interested in novel therapeutic targets for IBD.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
Researchers report that RADX, a regulator of replication-fork stability, competes with the DNA sensor IFI16 for single-stranded DNA. When RADX is lost, ssDNA accumulates, IFI16 is activated, and downstream NF-κB signaling and inflammasome assembly increase, driving intestinal inflammation in experimental models.
The paper notes two RADX gene variants found in patients with IBD that are associated with lower RADX protein levels, increased DNA-damage signaling, and higher IL-1β in the study samples.
In mice, pharmacologic inhibition of RAD51 (using the experimental inhibitor RI-1) reduced colitis severity, supporting the idea that modulating replication stress can alter inflammation.
This is a laboratory (preclinical) study that combines genetic, cellular, and mouse-model experiments to map a mechanistic pathway; it does not establish an approved treatment for patients.
Keep In Mind
Structured-content depth: abstract — the Cure8 brief is grounded in the article abstract and full-text extract provided. Findings are preclinical (cellular and mouse models) and mention genetic variants identified in patients, but clinical relevance and safety of targeting replication stress pathways in humans remain to be established.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationEMBO molecular medicine
AuthorsHuifang Xian, Wanming Huang, Zhanghua Chen +24 more
InstitutionDepartment of Gastroenterology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedJul 24, 2026, 12:00 AM
Content availableJournal abstract
Conflict statement: Disclosure and competing interests statement. The authors declare no competing interests.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Targeting IRF5 enhances S100A9-mediated granulocytic MDSC accumulation and suppressive function: a novel therapeutic strategy for ulcerative colitis.
This study points to a specific immune pathway (IRF5 repressing S100A9) that controls suppressive granulocytic MDSCs in ulcerative colitis, suggesting a new target for therapies aimed at modulating harmful inflammation.
Mechanism of recombinant Trichinella spiralis antigen p53 alleviating experimental colitis via the IDO-AhR Axis.
This study identifies an immune pathway (IDO–AhR) that a parasite-derived antigen appears to activate to reduce experimental colitis in mice. That pathway is relevant because it helps explain how immune regulation might...
NOX1 Drives Inflammatory Bowel Disease Through Oxidant-Dependent Stabilization of IκBζ.
Identifies a redox-sensitive NOX1–ROS–IκBζ pathway that may sustain intestinal inflammation in IBD and points to a new molecular target for future therapies.